SLAMF7 and Miyoshi myopathy: A novel BiAb was also developed to target another MM-specific antigen, CS1 (SLAMF7), and NKG2D on cytolytic immune cells (including NK cells, CD8+ T cells, γδ T cells, and NK-T cells), leading to effective MM lysis (83).